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Abstract
Background: Selective BRAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have been
approved for treatment of metastatic melanomas with a BRAF p.V600E mutation. The clinical significance of non-codon
600 mutations remains unclear, in part, due to variation of kinase activity for different mutants.
Methods: In this study, we categorized BRAF mutations according to the reported mutant kinase activity. A total of
1027 lung cancer, colorectal cancer or melanoma specimens were submitted for clinical mutation detection by next
generation sequencing.
Results: Non-codon 600 mutations were observed in 37 % of BRAF-mutated tumors. Of all BRAF mutants, 75 % were
kinase-activated, 15 % kinase-impaired and 10 % kinase-unknown. The most common kinase-impaired mutant involves
codon 594, specifically, p.D594G (c.1781A > G) and p.D594N (c.1780G > A). Lung cancers showed significantly higher
incidences of kinase-impaired or kinase-unknown mutants. Kinase-impaired BRAF mutants showed a significant
association with concomitant activating KRAS or NRAS mutations, but not PIK3CA mutations, supporting the
reported interaction of these mutations.
Conclusions: BRAF mutants with impaired or unknown kinase activity as well as concomitant kinase-impaired
BRAF mutations and RAS mutations were detected in lung cancers, colorectal cancers and melanomas. Different
therapeutic strategies based on the BRAF mutant kinase activity and the concomitant mutations may be worthwhile.
Keywords: BRAF, Lung cancer, Colorectal cancer, Melanoma, Next generation sequencing, Kinase activity, Concomitant
mutation
Background
The mitogen-activated protein kinase (MAPK) or RAS/
RAF/MEK/ERK signaling pathway regulates cell prolifera-
tion, differentiation and apoptosis [1]. This pathway is
often dysregulated in human cancers, frequently due to
activating mutations of the KRAS, NRAS, or BRAF genes.
Selective BRAF inhibitors like vemurafenib and dabrafenib
[2], and MEK inhibitors like trametinib have been devel-
oped to target BRAF mutant tumors [3]. Since the approval
of vemurafenib by the Food and Drug Administration
(FDA) of the United States in 2011 for treatment of
unresectable or metastatic melanomas with a BRAF
p.V600E mutation, clinical detection of the BRAF p.V600E
mutation has become the standard of care for patients with
metastatic melanoma in order to predict response to
vemurafenib, dabrafenib and trametinib [4–7].
The BRAF gene is mutated in approximately 7 % of hu-
man cancers overall [8], specifically, 40 % to 60 % of ma-
lignant melanomas [9], 10 % to 15 % of colorectal cancers
(CRCs) [10], and 1 to 5 % of non-small cell lung cancers
(NSCLC) [11, 12]. While p.V600E is the most common
mutation detected in many tumor types, more than 100
mutations within exons 11 and 15 of the BRAF gene have
been reported in the Catalog of Somatic Mutations in
Cancer (COSMIC) database, accessed on 03/10/15. The
clinical significance of non-codon 600 mutations is largely
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unknown. In our previous retrospective study for quality
assessment, next generation sequencing (NGS) demon-
strated a high analytic sensitivity and a broad reportable
range for clinical detection of BRAF mutations. Non-
p.V600E mutants constitute a significant portion of BRAF
mutations in different tumors: NSCLCs (86 %), melanomas
(34 %) and CRCs (23 %) [12]. Discovering the spectrum of
non-p.V600E BRAF mutations in different malignancies is
a first step toward understanding their clinical significance.
The role of BRAF mutations in the MAPK pathway is
complicated not only by the multiplicity of signaling mo-
lecular components but also the variation of kinase activity
for different BRAF mutants (Fig. 1). Most BRAF muta-
tions, including the most common p.V600E (c.1799 T >A)
mutation, cause upregulation of the kinase activity (kin-
ase-activated mutants). Meanwhile, kinase-impaired BRAF
mutants have also been reported [11, 13, 14]. While differ-
ent assay systems have been used to determine the mutant
kinase activity, most commonly, basal BRAF kinase activ-
ity was determined in vitro by measuring direct MEK
phosphorylation [8, 11, 13] or measuring ERK phos-
phorylation in a kinase cascade assay using purified
MEK and ERK proteins [15–17]. Wan et al. defined a
high-activity mutant by a basal BRAF kinase activity
higher than that of oncogenic RAS-activated wild-type
BRAF, an intermediate-activity mutant by a basal BRAF
kinase activity between those of wild-type BRAF and
oncogenic RAS-activated wild-type BRAF, and a kinase-
impaired mutant by a basal BRAF kinase activity lower
than that of wild-type BRAF [13]. Demonstration of in-
creased phosphorylation of BRAF and MEK proteins in
patient’s tumor cell lysates [18] or inhibition of mutant-
induced MEK and/or ERK phosphorylation by BRAF
inhibitors in cell culture systems [19, 20] was also used to
define kinase-activated mutants. Kinase-impaired mutants
were further grouped into reduced-activity mutants, which
could still induce MEK and ERK phosphorylation via acti-
vation of CRAF in cell culture system (Fig. 1), and silent-
activity (or dead) mutant which could not [13, 16, 21]. In
the presence of oncogenic RAS, however, the silent-activity
mutants could induce MEK and ERK phosphorylation via
activation of CRAF (Fig. 1) [22]. Since reduced-activity mu-
tants could still activate MEK/ERK via CRAF [11, 13, 14],
demonstration of mutant-induced MEK or ERK phos-
phorylation in cell culture systems without evidence of
inhibition of mutant-induced MEK or ERK phosphoryl-
ation by BRAF inhibitors was not sufficient to define a
kinase-activated mutant. Kinase-activated mutants and
kinase-impaired mutants promote MEK/ERK activation
and tumor progression through different mechanisms.
Categorization of BRAF mutations according to their kin-
ase activity and the presence of absence of concomitant
KRAS or NRAS mutations may shed light on different
therapeutic strategies to treat BRAF-mutated tumors.
Methods
Materials
The Johns Hopkins Medicine institutional review board
(IRB) granted approval to this study with waiver of consent.
A total of 1027 formalin-fixed paraffin-embedded (FFPE)
neoplastic specimens with a diagnosis of lung cancer, colo-
rectal cancer or melanoma were submitted to a Clinical
Fig. 1 Activation of MAPK pathway by kinase-activated, kinase-impaired and kinase-silent BRAF mutants through different mechanisms. Approved
or potential targeted therapies are selected based on kinase activity of the BRAF mutants and concomitant mutations of the BRAF and RAS (KRAS
or NRAS) genes. SBI: selective BRAF inhibitors; MEKI: MEK inhibitors; CI: CRAF inhibitors
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Laboratory Improvement Amendments (CLIA)-certified la-
boratory for mutation detection using a NGS platform
between April 2013 and September 2014. NGS failed in 36
(3.5 %) specimens. Fifty-two paired specimens and 3 speci-
mens from one patient showed the same mutation patterns
and were counted as one tumor per pair/triad for analysis
of the prevalence and spectrum of the BRAF mutations.
NGS data were available for clinical reporting in 510 lung
cancers, 275 CRCs and 152 melanomas. The age of patients
ranged from 33–90 (median: 65) for lung cancer speci-
mens, 25–90 (median: 57) for CRC specimens, and 20–94
(median: 61) for melanoma specimens. The proportion of
female patients was 55 % for lung cancer specimens, 45 %
for CRC specimens, and 36 % for melanoma specimens.
Metastatic tumors accounted for 44 % of lung cancer speci-
mens, 28 % of CRC specimens, and 55 % of melanoma
specimens. Fifteen melanoma specimens have been tested
for a negative p.V600E mutation using pyrosequencing
before NGS analysis. Tissue blocks with adequate tumor
cellularity were selected by pathologists who made the
diagnosis. One Hematoxylin & eosin (H&E) slide followed
by 5–10 unstained slides and one additional H&E slide
were prepared with PCR precaution. The H&E slides were
examined and marked by the pathologist for subsequent
macro-dissection of the FFPE neoplastic tissues from 3–10
unstained slides of 5- or 10-micron thick sections. DNA
was isolated from the area(s) designated by pathologists
using the Pinpoint DNA Isolation System (Zymo
Research, Irvine, CA), followed by further purification via
the QIAamp DNA Mini Kit (Qiagen, Valencia, CA) [23].
Tumor cellularity was also retrospectively reviewed by
two molecular pathologists (GZ and MTL) as 5 quintiles
(1–20 %, 21–40 %, 41–60 %, 61–80 % and 81–100 %). In
the presence of discrepancy, the mean value was applied.
Next generation sequencing (NGS)
NGS was conducted using AmpliSeq Cancer Hotspot Panel
(v2) for targeted multi-gene amplification as described pre-
viously [24, 25]. Briefly, we used Ion AmpliSeq Library Kit
2.0 for library preparation, Ion OneTouch 200 Template
Kit v2 DL and Ion OneTouch Instrument for emulsion
PCR and template preparation, and Ion PGM 200 Sequen-
cing Kit with Ion 318 Chip and Personal Genome Machine
(PGM) as the sequencing platform (Life Technologies,
Carlsbad, California), all per manufacturers’ protocol. The
DNA input for targeted multi-gene PCR was up to 30 ng
measured by Qubit 20 Fluorometer (Life Technologies). Up
to 8 specimens were barcoded using Ion Xpress Barcode
Adapters (Life Technologies) for each Ion 318 chip. One to
three controls (non-template control, a normal peripheral
blood control from a male, and/or positive control speci-
mens.) were included in each run. The positive control
specimens were prepared from mixture of several cell lines
to include mutations in the AKT, BRAF, EGFR, ERBB2,
KIT, KRAS, NRAS and/or PIK3CA genes.
Sequencing data of the targeted genes were analyzed
using Torrent Suite (Life Technologies). Lung cancer
specimens were tested for AKT, BRAF, EGFR, ERBB2,
KRAS, NRAS and PIK3CA genes (lung cancer panel),
CRC specimens were tested for BRAF, KRAS, NRAS and
PIK3CA genes (CRC panel), and melanoma specimens
were tested for BRAF, KIT, NRAS and PIK3CA genes
(melanoma panel). KRAS mutations were also analyzed
for the melanoma specimens. The reference mRNA se-
quence was NM_005163 for AKT, NM_004333 for BRAF,
NM_033360 for KRAS, NM_002524 for NRAS, and
NM_006218 for PIK3CA. Mutations were identified and
annotated through both Torrent Variant Caller and direct
visual inspection of the binary sequence alignment/map
(BAM) file on the Broad Institute’s Integrative Genomics
Viewer (IGV) (http://www.broadinstitute.org/igv/). IGV
was also used to determine the coverage of each specific
exon and to confirm the number of reads of the variants.
Novel mutations not reported in the database of COSMIC
were confirmed by Sanger sequencing or pyrosequencing
as described previously [12]. During our validation of this
NGS assay, a cutoff of background noise at 2 % was
chosen for single nucleotide variations according to a
study of 16 non-neoplastic FFPE tissues [24]. With suffi-
cient DNA input, the limit of detection is dictated by the
depth of coverage (or number of sequencing reads).
Approximately 150 and 500 reads is needed to detect a
heterozygous mutation at a 99 % confidence in a specimen
with 20 % and 10 % tumor cellularity, respectively. During
the period between April 2013 and September 2014, the
coverage of exon 11 and exon 15 of the BRAF gene was
1705 ± 1368 and 2182 ± 1540 reads (mean ± standard devi-
ation), respectively.
Single Nucleotide Polymorphism (SNP) array
SNP array analysis was performed as previously described
[26]. Briefly, DNA samples extracted from FFPE tissues
(optimally 200 ng) were treated with the Infinium HD
FFPE NDA restore kit before running on the Illumina Infi-
nium II SNP array (HumanCytoSNP-12 v2.1 DNA Ana-
lysis BeadChip, Illumina Inc., San Diego, CA) according to
manufacturer’s standard protocol. The B allele frequency
and Log R ratio data were analyzed using Illumina
KaryoStudio software version 2.0 and CNV (copy number
variation) partition V2.4.4.0.
Reported mutant kinase activity to categorize BRAF
mutations observed in the clinical specimens
The majority of mutations are predicted to cause elevation
of the kinase activity (Table 1). The degree of elevation varied
[13]. Mutations at codon 600 showed several hundred fold
elevation of kinase activity while others showed less than 100
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fold elevation. Impaired-kinase mutants involving codons
466, 469, 472, 483, 594, 596, 599 and 602 have been re-
ported. The highly conserved aspartic acid residue encoded
by codon 594 is a part of the DFG motif that plays an
important role in chelating magnesium and stabilizing
ATP binding [22]. Mutations at codon 594 of the BRAF
genes lead to a severely reduced or silent/dead kinase with
no direct or indirect activity on the downstream MAPK
pathway in the absence of oncogenic RAS [13, 16, 22].
Mutations at the same codon may cause activated or
impaired kinase activity depending on the specific muta-
tion. Replacement of the conserved phosphorylation sites
at codon 599 and 602 by a non-polar amino acid (such as
p.T599A and p.S602A) results in complete abortion of the
kinase activity while replacement by an acidic amino acid
(such as p.T599E and p.S602D) leads to RAS-independent
BRAF activation [17]. A discrepancy has been reported
when the codon 599 residue was replaced by a bulky non-
polar amino acid, isoleucine (p.T599I mutant) [13, 16].
The p.T599I mutant was categorized as an intermediate-
activity mutant by direct measurement of MEK phosphor-
ylation using ATP at a physiological concentration, but
showed a slightly deceased basal kinase activity (0.84 fold)
by measuring ERK phosphorylation using BRAF kinase
cascade assay with ATP at a sub-physiological concentra-
tion. Another example occurs at codon 469 of the P loop
which is wedged against codon 597 of the activation
segment. Replacement by alanine (p.G469A) showed a
200-fold increase of basal kinase activity compared to
replacement by bulky glutamic acid (p.G469E) [13]. While
p.G469E was categorized as an intermediate-activity mu-
tant, it has the lowest kinase activity within this category
(1.8 fold increase) [13]. In contrast, Smalley et al. demon-
strated reduced kinase activity of p.G469E mutation [21].
In the following analysis of clinical specimens, p.T599I
and p.G469E were therefore grouped into the kinase-
unknown category.
Statistics
Correlation between BRAF mutant allele frequency and
KRAS or NRAS mutant allele frequency was examined
by Spearman’s rank correlation coefficient (denoted as r)
using the GraphPad Prism software (GraphPad Software,
ver5, La Jolla, CA).
Results
Clinical detection of BRAF mutations in different tumors
according to kinase activity
BRAF mutations were detected in 33 of 510 (6.5 %)
NSCLCs, 34 of 275 (12 %) CRCs, and 67 of 152 (44 %)
melanomas, including a melanoma specimen with
both p.V600E (c.1799 T > A) mutation and p.S605I
(c.1814G >T) occurring in the same allele (Table 2). The
coverage of a BRAF mutation was 585 ± 548 reads (mean ±
standard deviation). As expected, the most common
residue involved by the BRAF mutation was codon 600
(86/135, 64 %), followed by codon 594 (15/135, 11 %).
Non-codon 600 mutations, p.S467L (c.1400C > T) and
p.G594N (c.1780G > A), were detected in 2 of 15 mela-
nomas with prior negative pyrosequencing for codon
600. There was a significant higher fraction of non-
codon 600 mutation in NSCLCs (26/33, 79 %) than
those in CRCs (7/34, 21 %, P < 0.001) and melanomas
(16/68, 24 %, P < 0.001).
Kinases activity is predicted to be elevated in 101 of
135 (75 %) BRAF mutations, impaired in 20 (15 %) and
unknown in 14 (10 %). Unique mutations detected in
only one tumor were observed in 4 of 10 unique kinase-
activated mutants, 4 of 8 kinase-impaired mutants and
Table 1 Effects of BRAF mutations on serine-threonine kinase
activity
Activated [references] Impaired [references]
R462Ia [13] G466E [13, 15]
I463Sa [13] G466R [15]
G464Ea [13] G466V [11, 13]
G464R [15] G469Ec [21]
G464Va [8, 13] Y472C [11]
G466Aa [13] K483Mb [13, 22]
G469Aa [8, 11, 13] D594Ab [22]
G469Ea,c [13] D594Gb [21]
N581Sa [13] D594Vb [13, 16, 22]
E586K [13] G596R [13, 16]
F595La [13, 16] T599A [17]
L597Q [19] T599Id [16]
L597R [19, 20] S602A [17]
L597S [19]





V600E [8, 11, 13, 16]
V600K [13, 15]
V600R [13, 15]
K601E [13, 16, 19]
S602D [17]
A728Va [13]
acategorized as intermediate activity mutants by Wan et al. [13]
bcategorized as severely reduced or silent/dead activity mutants
ccategorized as intermediate activity (only1.8 fold increase) by Wan et al. [13]
but reduced activity by Smalley et al. [21]. In the analysis of clinical specimens,
p.G469E was grouped into the kinase-unknown category
dcategorized as intermediate activity by Wan et al. [13], but reduced activity
(0.84 fold) by Ikenoue et al. [16]. In the analysis of clinical specimens, p.T599I
was grouped into the kinase-unknown category
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10 of 12 kinase-unknown mutants. The exceptions for the
kinase-unknown mutant were p.G469E (c.1406G > A) and
p.G469V (c.1406G > T). The most common residue
involved by the kinase-impaired mutant was codon 594
(15 of 20 or 75 % of kinase-impaired mutants), specific-
ally, p.D594G (c.1781A > G) in 8 tumors and p.D594N
(c.1780G > A) in 5 tumors. Mutations involving codon
594 were observed in 7 (1.4 %) of 510 lung cancers, 4
Table 2 BRAF mutation in lung cancers, CRCs and melanomas
Kinase
activity
Mutation NSCLC CRC Melanoma Total
(n = 510) (n = 275) (n = 152) (n = 937)
Activated
G464V (c.1391G > T) 2 2
G466A (c.1397G > C) 2 1 3
G469A (c.1406G > C) 1 1
N581S (c.1742A > G) 2 2
L597Q (c.1790 T > A) 1 1
L597R (c.1790 T > G) 1 1
V600E (c.1799 T > A)a 7 27 44 78
V600K (c.1798_1799delinsAA) 7 7
V600R (c.1798_1799GT > AG) 1 1
K601E (c.1801A > G) 3 2 5
Total 15 (2.9 %) 29 (11 %) 57 (38 %) 101
Impaired
G466R (c.1396G > A) 1 1
G466V (c.1397G > T) 1 1 2
Y472C (c.1415A > G) 1 1
D594E (c.1782 T > G) 1 1
D594G (c.1781A > G) 4 3 1 8
D594H (c.1780G > C) 1 1
D594N (c.1780G > A) 2 1 2 5
G596R (c.1786G > C) 1 1
Total 10 (2.0 %) 5 (1.8 %) 5 (3.3 %) 20
Unknown
T440I (c.1319C > T)b 1 1
S467L (c.1400C > T) 1 1
G469E (c.1406G > A) 2 2
G469R (c.1405G > A) 1 1
G469S (c.1405_1406delinsTC) 1 1
G469V (c.1406G > T) 1 1 2
L584F (c.1750C > T) 1 1
L588F (c.1762C > T) 1 1
V600_K601delinsE (c.1799_1801del)b 1 1
S605I (c.1814G > T)b 1 1
Q609L (c.1825_1826delinsTT)b 1 1
E611Q (c.1831G > C)b 1 1
Total 8 (1.6 %) 0 6 (3.9 %) 14
Total 33 (6.5 %) 34 (12 %) 68/67c (44 %) 135/134c
aincluding a melanoma specimen with c.1799_1800delinsAA (p.V600E2)
bmutations not reported in the COSMIC database (last assessment on August 7, 2015)
cincluding a melanoma specimen with both p.V600E and p.S605I mutations
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(1.5 %) of 275 CRCs sand 4 (2.6 %) of 152 melanomas.
Other kinase-impaired mutants included p. G466R
(c.1396G > A), p.G466V (c.1397G > T), p.Y472C (c.1415
A > G) and p.G596R (c.1786G > C). Six of 14 kinase-
unknown mutants were seen in codon 469. Among
those tumors with a BRAF mutation, NSCLCs showed a
significant lower incidence of kinase-activated mutants
(45 %) as compared to CRCs (85 %) and melanomas
(84 %) and a higher incidence of kinase-impaired mu-
tants or kinase-unknown mutants (Fig. 2). BRAF muta-
tions with unknown kinase activity were not seen in
CRC specimens.
Concomitant mutations of MAPK pathway
No concomitant BRAF and EGFR or ERBB2 mutation was
observed in NSCLC specimens. The frequency of con-
comitant KRAS or NRAS mutations found in a BRAF-mu-
tated tumor was 4 of 33 (12 %) in NSCLCs, 3 of 34 (8.8 %)
in CRCs, or 3 of 67 (4.5 %) in melanomas (Table 3). An
NSCLC specimen showed an additional KRAS p.V8I
(c.22G >A) mutation in the same allele of p.G13D
(c.38G >A) mutation (case P10) and a melanoma speci-
men showed an addition PIK3CA p.P75S (c.169C > T)
mutation (case P8). All except KRAS p.G15S (c.43G >A)
in case P2 were activating KRAS or NRAS mutations at
codon 12, 13, 59 or 61. Concomitant BRAF and activating
RAS mutations were observed in 0 of 86 specimens with
codon 600 mutations and in 9 of 49 specimens (18 %)
with non-codon 600 mutations (Fig. 3). Concomitant
BRAF and activating RAS mutations were observed in 2 of
101 (2.0 %) kinase-activated mutants, 3 of 20 (15 %)
kinase-impaired mutants, and 4 of 14 (29 %) kinase-
unknown mutants (Fig. 3).
BRAF mutant allele frequencies were highly concordant
with the KRAS and NRAS mutant allele frequencies
(Fig. 4), suggesting that concomitant mutations are
present in the same tumor population. A discrepancy was
observed in cases P1 with a higher KRAS mutant allele
frequency (49 % vs. 30 %), case 2 with a much lower KRAS
p.G15S (c.43G > A) allele frequency (8.4 % vs. 29 %), and
case P6 with a much lower BRAF p.D594N (c.1780G > A)
allele frequency (5.7 % vs. 24 %). Pyrosequencing was per-
formed in DNA specimens isolated from 3 subareas of
case P1. The KRAS/ BRAF mutant allele ratio was 2.04
(49 % vs. 24 %), 1.72 (50 % vs. 29 %) and 1.59 (53 % and
34 %), respectively. SNP array analysis of case P1 revealed
gain of chromosome 12p containing the KRAS gene.
These results indicate that concomitant KRAS and BRAF
mutations are present within the same tumor cells with
amplification of the KRAS mutant allele. In case P2, the
BRAF p.V600E (c.1799 T > A) mutant allele frequency
(29 %) was consistent with the estimated tumor cellularity
(41–60 %), suggesting KRAS p.G15S (c.43G > A) was
present in a subpopulation of tumor. This was confirmed
by the presence of BRAF p.V600E (c.1799 T > A) mutation
in all 4 subareas, but KRAS p.G15S (c.43G > A) mutation
(16 % vs. 34 % of BRAF p.V600E) in only one of 4 sub-
areas. SNP array showed no aneuploidy of both chromo-
somes 12 and 7 containing KRAS gene and BRAF gene,
respectively. Similarly in case P6, the BRAF p.D594N
(c.1780G > A) mutant was also likely present in a subpop-
ulation of tumors.
The presence of 40 % BRAF and KRAS mutations in the
context of 71–90 % estimated tumor cellularity in case P4
and the presence of 31 % BRAF mutation and 30 % KRAS
mutation in the context of 51–70 % estimated tumor
cellularity in case P5 suggest that the kinase-impaired
BRAF mutation and the activating KRAS mutation were
present in the all the tumor cells. KRAS/BRAF mutant
allele ratio was consistently 1:1 (1.05, 1.06 and 1.00 by py-
rosequencing) in 3 subareas re-isolated from cases P5, fur-
ther supporting the presence of concomitant mutations in
the same tumor cell population instead of different tumor
subpopulations.
Concomitant mutations of mTOR pathway
Concomitant BRAF and AKT mutations were observed in
2 lung adenocarcinomas (Table 4), both of which had a
BRAF p.V600E (c.1799 T > A) mutation. BRAF mutations
accompanied by a PIK3CA mutation were observed in 2
Fig. 2 Distribution of kinase-activated, kinase-impaired and
kinase-unknown BRAF mutants. Non-small cell lung cancers
(NSCLCs) showed higher incidences of kinase-impaired and
kinase-unknown BRAF mutants as compared to colorectal cancers
(CRCs) and melanomas
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of 33 (6.1 %) BRAF-mutated lung cancers, 4 of 34 (12 %)
BRAF-mutated CRCs, and 2 of 67 (3.0 %) BRAF-mutated
melanomas (Table 4). Concomitant BRAF and PIK3CA
mutations were observed in 4 of 86 specimens (4.7 %) with
a codon 600 mutation and in 4 of 49 specimens (8.2 %)
with a non-codon 600 mutation (P = 0.46 by Fisher exact
test). Concomitant PIK3CA mutations were observed in 4
of 101 (4.0 %) elevated-activity BRAF mutants, 1 of 20
(5.0 %) reduced-activity mutants, and 3 of 14 (21 %)
unknown-activity mutants.
Table 3 Concomitant BRAF mutations with KRAS or NRAS mutations in the MAPK pathway
Kinase activity Diagnosisa BRAFb RASc
Activated
Case P1 Melanoma (71–90 %) G466Ad (30 %) KRAS/G12D (49 %)
Case P2 colorectal cancer (41–60 %) V600E (29 %) KRAS/G15S (8.4 %)
Case P3 Melanoma (61–80 %) K601E (35 %) NRAS/G13N (34 %)
Impaired
Case P4 Colorectal cancer (71–90 %) Y472C (40 %) KRAS/G12V (40 %)
Case P5 Colorectal cancer (51–70 %) D594G (31 %) KRAS/A59E (30 %)
Case P6 Lung cancer (51–70 %) D594N (5.7 %) KRAS/Q61H (24 %)
Unknown
Case P7 Lung cancer (41–60 %) T440I (13 %) KRAS/G12V (16 %)
Case P8e Melanoma (61–80 %) S467L (26 %) NRAS/Q61K (24 %)
Case P9 Lung cancer (21–40 %) G469R (11 %) KRAS/G12R (12 %)
Case P10 Lung cancer (41–60 %) G469V (20 %) KRAS/G13D (25 %)
aEstimated tumor cell percentage of the specimens was indicated in the parenthesis
bNucleotide changes of BRAF mutations were shown in Table 2. Percentage in the parenthesis indicates mutant allele frequency
cactivating KRAS or NRAS mutations except KRAS p.G15S (c.43G > A) of unknown significance. G12V: c.35G > T;; G12R: c.34G > C; G13D: c.38G > A; A59E: c.176C > A;
Q61H: c.183A > C; Q61K: c.181C > A. Percentage in the parenthesis indicates mutant allele frequency
dintermediate -activity mutant by Wan et al. [13]
esame case as M8 with BRAF, NRAS and PIK3CA mutations in Table 4
Fig. 3 Incidence of concomitant BRAF and activated RAS (KRAS or NRAS)
mutations. Higher incidences of concomitant BRAF and activated RAS
mutations are seen in non-codon 600 BRAF-mutated tumors (left) and in
BRAF-mutated tumors with impaired or unknown kinase activity (right)
Fig. 4 Correlation of mutant allele frequencies in tumors with
concomitant BRAF and activating RAS mutations. The lines labeled
with 80 % and 120 % indicate the boundary of events with the BRAF/
RAS mutant allele ratio between 80 % and 120 %. r: Spearman’s rank
correlation coefficient
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Discussion
BRAF mutations show diverse functional consequences
and varied response to BRAF inhibitors. In this study, we
categorized BRAF mutations detected in NSCLCs, CRCs
and melanomas into kinase-activated mutants (75 %),
kinase-impaired mutants (15 %) and kinase-unknown mu-
tants (10 %) according to the functional studies reported in
the literature. NSCLCs showed a significantly lower inci-
dence of kinase-activated mutants than those of CRCs and
melanomas. Mutations at codon 594 accounted for 11 % of
BRAF mutations and were the most common kinase-
impaired ones. We also demonstrated that concomitant
KRAS or NRAS mutations, but not PIK3CA mutations,
more likely occur with the kinase-impaired BRAF mutants
than the kinase-activated ones.
While some BRAF mutations could be passenger muta-
tions, especially those with impaired or unknown kinase
activity, most BRAF mutations with elevated kinase activity
are likely involved in oncogenesis and thus could be target-
able. Choices of the inhibitors or inhibitor combinations
are at least partly made based on BRAF mutation status.
In our study, p.V600E (c.1799 T >A) was the most com-
mon BRAF mutation, occurring in 27 of 34 (79 %) CRCs,
44 of 68 (65 %) melanomas and 7 of 33 (21 %) NSCLCs.
Non-p.V600E codon 600 mutations were seen in 8 of 68
(12 %) BRAF-mutated melanomas. The selective inhibitors
of BRAF codon 600 mutants, vemurafenib and dabrafenib,
have been shown to improve progression-free and overall
survival in metastatic melanoma patients, with either the
p.V600E mutation or non-p.V600E mutations at codon
600, such as p.V600K and p.V600R [4, 27–29]. Responding
to vemurafenib or dabrafenib has been observed in few
NSCLC patients with a BRAF p.V600E mutation [30–33],
although the exact benefit of selective BRAF inhibitors for
lung cancer patients is currently still under investigation
[34]. Whether BRAF inhibitors benefit patients with a
kinase-activated BRAF mutation located outside codon
600 remains less clear, although a partial response to
vemurafenib has been reported in a melanoma patient
with a p.L597R mutation [20]. Responsiveness to MEK
inhibitors (TAK-733 and trametinib) in melanoma pa-
tients with a codon 597 mutations or p.K601E mutation
suggests that future clinical trials of MEK inhibitors in
patients with kinase-activated non-codon 600 muta-
tions should be considered [19, 35, 36].
BRAF mutations with reduced kinase activity are un-
likely responsive to BRAF inhibitors. These mutants, how-
ever, can still drive MAPK pathway through activation of
CRAF/MEK/ERK cascade (Fig. 1) [13, 14]. In vitro studies
of kinase-reduced mutants such as p.G466V, p.G466E and
p.G596R, have also shown that activation of the CRAF/
MEK/ERK cascade can be inhibited by MEK inhibitors or
sorafenib, an inhibitor for multiple kinase including CRAF.
In a previous clinical trial of dasatinib, a tyrosine kinase
inhibitor, for metastatic non-small cell lung cancer, a
patient with BRAF p.Y472C mutation remained 4-year
disease-free after treatment [11]. In vitro studies con-
firmed the activation of CRAF/MEK/ERK cascade by
the kinase-impaired p.Y472C mutant and demonstrated
dasatinib-induced senescence and apoptosis in lung
cancer cells expressing kinase-impaired p.G466V mu-
tant, but not in cell lines with kinase-activated BRAF
mutants.
Mutations with silent/dead kinase activity are unlikely re-
sponsive to either BRAF or MEK inhibitors. Mutations
with silent/dead kinase activity have been reported in
p.D594V, p.D594A and p.K483M mutations of the BRAF
gene [13, 16, 22]. Codon 483 encodes the catalytic lysine
and the aspartic acid at codon 594 is part of the DFG motif
that plays an important role in chelating magnesium and
stabilizing ATP binding [22]. Mutations at codon 483 or
594 genes lead to silence of the kinase activity with no dir-
ect or indirect activation on the downstream MAPK path-
way [13, 16, 22]. Mutations at codon 594, however, have
been associated with a higher incidence of co-existent RAS
mutation (4 in 34, 12 %) as compared to p.V600E and pre-
sumably may also cooperate with mutations within the
upstream of RAS or inter-connected pathways [22]. In this
study, mutations at codon 594 constituted the second most
common BRAF mutations in NSCLCs (7/33, 21 %), CRCs
(4/34, 12 %) and melanomas (4/68, 5.9 %). Concomitant
activating RAS mutations were observed in 2 of 15 (13 %)
codon 594 mutations, but none of 86 codon 600 muta-
tions. In the presence of oncogenic RAS proteins, kinase-
Table 4 Concomitant BRAF mutations with AKT or PIK3CA
mutations in the mTOR pathway
Kinase activity Diagnosis BRAFa AKTb/PIK3CAc
Activated
Case M1 lung cancer V600E (13 %) AKT/E17K (13 %)
Case M2 lung cancer V600E (24 %) AKT/E17K (30 %)
Case M3 lung cancer V600E (6.2 %) PIK3CA/R88Q (5.7 %)
Case M4 colorectal cancer V600E (24 %) PIK3CA/E545K (29 %)
Case M5 colorectal cancer V600E (19 %) PIK3CA/H1047Q (25 %)
Case M6 colorectal cancer V600E (42 %) PIK3CA/H1047R (39 %)
Impaired
Case M7 melanoma D594N (59 %) PIK3CA/L327F (19 %)
Unknown
Case M8d melanoma S467L (26 %) PIK3CA/P57S (23 %)
Case M9 colorectal cancer N581S (30 %) PIK3CA/K111E (32 %)
Case M10 lung cancer E611Q (18 %) PIK3CA/D350N (13 %)
Percentage in the parenthesis indicates mutant allele frequency
aNucleotide changes of BRAF mutations were shown in Table 2
bE17K: c.49G > A
cP57S: c.169C > T; p.R88Q (c.263G > A); p.K111E (c.331A > G); L327F: c.979C > T;
D350N: c.1048G > T; p.E545K: c.1633G > A; p.H1047Q (c.3141 T > G);
p.H1047R: c.3140A > G
dsame case as P8 with BRAF, NRAS and PIK3CA mutations in Table 3
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silent BRAF forms a complex with CRAF and lead to hy-
peractivation of the CRAF/MEK/ERK cascade (Fig. 1) [22].
These preclinical studies suggested that MEK inhibitors or
CRAF inhibitors may benefit patients with concomitant
kinase-silent BRAF mutation and activating RAS mutation.
In contrast to the absence of concomitant BRAF
p.V600E mutation and activating RAS mutation, 3 of 7
(43 %) NSCLCs and 3 of 27 (11 %) CRCs with a
p.V600E (c.1799 T > A) showed a concomitant mutation
in the AKT or PIK3CA genes of the mTOR pathway. In
the step-wise genetic alteration model associated with colo-
rectal tumorigenesis, PIK3CA mutations occur after KRAS
or BRAF mutations and, in cooperation with other muta-
tions, drive clonal evolution from large adenoma to inva-
sive adenocarcinoma [37]. Thus it is not surprising to see
concomitant PIK3CA mutations in 11 % of CRCs with a
BRAF p.V600E (c.1799 T >A) mutation, similar to a 16 %
of CRCs with an activating KRAS mutation (data not
shown) in this cohort. Activating PIK3CA p.H1047R muta-
tion has also been shown to cooperate with BRAF p.V600E
mutation to promote progression of benign lung tumors to
lung cancers [38]. Mutations in the AKT and PIK3CA
genes, however, are uncommon in NSCLCs. PIK3CA mu-
tations have been detected in approximately 2 % of lung
adenocarcinomas [39]. The AKT p.E17K mutation was
seen in only 2 of 509 NSCLCs [40–43]. In this study, the
AKT p.E17K mutation was only detected in two lung
adenocarcinomas with a BRAF p.V600E (c.1799 T >A)
mutation, suggesting the cooperation between the MAPK
and mTOR pathways, similar to that between the KRAS,
NRAS or BRAF mutation and PIK3CA mutation.
In general, initiating driving mutations within the same
pathway are mutually exclusive. In the setting of clinical
diagnosis, caution has to be taken for interpretations of
“double initiating mutations” within the same pathway.
Mutations in the KRAS, NRAS and PIK3CA genes have
been the mechanisms for both innate and acquired resist-
ance to targeted therapeutics with kinase inhibitors or anti-
EGFR antibodies [34]. In this study, none of patients with
concomitant mutations received kinase inhibitors or anti-
EGFR antibodies. In the presence of concomitant PIK3CA
or AKT mutations, a combination of BRAF inhibitors or
MEK inhibitors with mTOR pathway inhibitors may be
more effective [44]. Correlation of the mutant allele fre-
quencies with the estimated tumor frequency may be
applied to elucidate if concomitant mutations are present
in the same tumor population or only in a subpopulation.
The consistency of mutant allele ratios, when testing differ-
ent random subareas, would further support that concomi-
tant mutations are present in the same population.
Conclusion
In this study, we categorized BRAF mutations accord-
ing to the reported kinase activity and showed that
concomitant KRAS or NRAS mutations more likely
occur with the kinase-impaired BRAF mutants than the
kinase-activated BRAF mutants. Different therapeutic
strategies should be developed based on BRAF mutant
kinase activity and the concomitant mutations.
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